Wave Life Sciences in a Tuesday filing with the SEC said Takeda has elected to terminate its option to continue work on ...

RNA specialist Wave Life Sciences has been told by Takeda that the Japanese drugmaker is to bring to an end the last facet of ...

Takeda is walking away from the last target in a collaboration with Wave Life Scien | Takeda has brandished a termination ...

Wave Life Sciences (NASDAQ:WVE) said Takeda (NYSE:TAK) has elected not to exercise its option to further develop its ...

Takeda Pharmaceutical offers a strong cash position and an above-average dividend yield. Find out why I'm bullish on TAK ...

There is no simple solution to tackling health inequity, but we’re confident that infusing health equity principles across ...

Wave Life Sciences' WVE-006 study shows significant promise in treating alpha-1 antitrypsin deficiency. Learn more about WVE ...

Takeda, a global pharmaceutical leader, is celebrating a decade in Vietnam, emphasizing its commitment to improving ...

Pharmaceutical company Lupin has announced a non-exclusive patent licence agreement with Takeda Pharmaceutical for the ...

More Than 22,000 Takeda Employees Selected the FY2024 New Partners: Population Services International, Bulungula Incubator, Reach Out Cameroon, Seed Global Health and VillageReach Takeda’s Five ...

The T. Rowe Price Japan Fund (Trades, Portfolio), known for its strategic investments in a diverse array of Japanese industries, has recently disclosed its N-PORT filing for the third quarter of 2024.

Gastrointestinal virtual care company Oshi Health announced a $60 million series C round led by Oak HC/FT.  | Virtual GI care ...